View Future GrowthFormycon 과거 순이익 실적과거 기준 점검 0/6Formycon 의 수입은 연평균 -42.8%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 11.1%의 비율로 증가해 왔습니다.핵심 정보-42.85%순이익 성장률-33.89%주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률11.06%자기자본이익률-16.21%순이익률-145.46%다음 순이익 업데이트28 May 2026최근 과거 실적 업데이트Reported Earnings • Apr 24Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: €3.66 loss per share (improved from €7.19 loss in FY 2024). Revenue: €44.5m (down 36% from FY 2024). Net loss: €64.7m (loss narrowed 49% from FY 2024). Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 81%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.공시 • Apr 16Formycon AG to Report Fiscal Year 2025 Results on Apr 22, 2026Formycon AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 22, 2026공시 • Dec 30+ 3 more updatesFormycon AG to Report Fiscal Year 2025 Results on Mar 26, 2026Formycon AG announced that they will report fiscal year 2025 results on Mar 26, 2026Reported Earnings • Aug 19First half 2025 earnings released: €3.07 loss per share (vs €0.58 loss in 1H 2024)First half 2025 results: €3.07 loss per share (further deteriorated from €0.58 loss in 1H 2024). Revenue: €9.00m (down 67% from 1H 2024). Net loss: €54.2m (loss widened 437% from 1H 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 30Full year 2024 earnings released: €7.19 loss per share (vs €4.76 profit in FY 2023)Full year 2024 results: €7.19 loss per share (down from €4.76 profit in FY 2023). Revenue: €69.7m (down 10% from FY 2023). Net loss: €125.7m (down 266% from profit in FY 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.공시 • Jan 02+ 2 more updatesFormycon AG to Report Q1, 2025 Results on May 15, 2025Formycon AG announced that they will report Q1, 2025 results on May 15, 2025모든 업데이트 보기Recent updates공시 • May 05Formycon AG, Annual General Meeting, Jun 10, 2026Formycon AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.내러티브 업데이트 • Apr 30FYB: Future Earnings Guidance And Biosimilar Progress Will Support Bullish OutlookAnalysts have raised their price target for Formycon from €35.69 to €40.14, citing updated assumptions around revenue growth, profit margins, and the P/E multiple used in their models. What's in the News Formycon issued earnings guidance for 2026, with the group expecting revenue in a range of €60.0 million to €70.0 million.Reported Earnings • Apr 24Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: €3.66 loss per share (improved from €7.19 loss in FY 2024). Revenue: €44.5m (down 36% from FY 2024). Net loss: €64.7m (loss narrowed 49% from FY 2024). Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 81%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.공시 • Apr 16Formycon AG to Report Fiscal Year 2025 Results on Apr 22, 2026Formycon AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 22, 2026New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Major Estimate Revision • Mar 08Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.81 to -€2.09 per share. Revenue forecast of €55.2m unchanged since last update. Biotechs industry in Germany expected to see average net income growth of 16% next year. Consensus price target down from €41.86 to €40.71. Share price fell 14% to €19.74 over the past week.새로운 내러티브 • Feb 09Regulatory Tailwinds And Biosimilar Royalties Will Slowly Overcome Concentrated Pipeline RisksCatalysts About Formycon Formycon develops and commercializes biosimilar medicines in collaboration with partners across global markets. What are the underlying business or industry changes driving this perspective?새로운 내러티브 • Jan 24Regulatory Tailwinds And Biosimilar Pipeline Will Reshape Long Term Earnings PowerCatalysts About Formycon Formycon develops and commercializes biosimilar medicines, focusing on high-value biologics in ophthalmology, immunology and oncology. What are the underlying business or industry changes driving this perspective?Buy Or Sell Opportunity • Jan 15Now 21% undervaluedOver the last 90 days, the stock has risen 3.9% to €24.20. The fair value is estimated to be €30.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 61% in a year. Earnings are forecast to grow by 91% in the next year.공시 • Dec 30+ 3 more updatesFormycon AG to Report Fiscal Year 2025 Results on Mar 26, 2026Formycon AG announced that they will report fiscal year 2025 results on Mar 26, 2026New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.New Risk • Nov 20New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €170m Forecast net loss in 2 years: €560k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.Major Estimate Revision • Nov 15Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from €54.2m to €54.9m. EPS estimate increased from -€2.16 per share to -€1.91 per share. Biotechs industry in Germany expected to see average net income growth of 22% next year. Consensus price target of €43.63 unchanged from last update. Share price rose 7.5% to €20.75 over the past week.Major Estimate Revision • Aug 31Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.88 to -€2.11 per share. Revenue forecast unchanged at €54.9m. Biotechs industry in Germany expected to see average net income growth of 15% next year. Consensus price target of €43.75 unchanged from last update. Share price was steady at €24.15 over the past week.Major Estimate Revision • Aug 20Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €56.4m to €54.9m. Losses expected to increase from €1.69 per share to €1.90. Biotechs industry in Germany expected to see average net income growth of 16% next year. Consensus price target broadly unchanged at €43.75. Share price was steady at €24.60 over the past week.Reported Earnings • Aug 19First half 2025 earnings released: €3.07 loss per share (vs €0.58 loss in 1H 2024)First half 2025 results: €3.07 loss per share (further deteriorated from €0.58 loss in 1H 2024). Revenue: €9.00m (down 67% from 1H 2024). Net loss: €54.2m (loss widened 437% from 1H 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Aug 05Consensus EPS estimates fall by 21%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.40 to -€1.69 per share. Revenue forecast unchanged at €56.4m. Biotechs industry in Germany expected to see average net income growth of 16% next year. Consensus price target broadly unchanged at €44.25. Share price fell 14% to €25.40 over the past week.공시 • Jul 11Formycon AG Completes Patient Enrollment for the Clinical Development of Its Keytruda®? Biosimilar Candidate FYB206Formycon AG announced that the patient enrollment for the clinical PK study Dahlia has been successfully completed with a total of 96 participants (Last Patient-In). The Dahlia study, which was launched in June 2024 in selected Southeastern and Eastern European study centers, compares the pharmacokinetics, safety and tolerability of FYB206 with the immuno-oncology blockbuster drug Keytruda®?2. At the end of 2024, Formycon submitted a streamlined clinical strategy to the U.S. Food and Drug Administration (FDA) with the intention to demonstrate the therapeutic comparability of FYB206 With the reference drug Keytruda®? based on comprehensive analytical data and data from the PK study (Dahlia). Following a positive response from the FDA, the company decided in February 2025 to discontinue recruitment for the already-started Phase III trial. This decision accelerates the development of the biosimilar and at the same time significantly reduces the related investments over the coming years. The treatment of patients already enrolled in the Phase III trial has subsequently been continued with the locally available Keytruda®? outside the trial. With streamlined clinical development program for FYB206, have secured a leading role among the developers of a pembrolizumab biosimilar. This is further underlined by the efficient and reliable execution of the Dahlia PK study. The first patients in the Dahlia trial have already completed all 17 treatment cycles. therefore currently expect to receive the results of the study endpoint in the first quarter of 2026.Price Target Changed • Jul 01Price target decreased by 11% to €44.13Down from €49.33, the current price target is an average from 8 analysts. New target price is 60% above last closing price of €27.55. Stock is down 50% over the past year. The company is forecast to post a net loss per share of €1.37 next year compared to a net loss per share of €7.18 last year.공시 • Jun 20Formycon Ag Elects Graham Keith Dixon as A New Member of the Supervisory BoardFormycon AG announced that Graham Keith Dixon elected as a new member of the Supervisory Board.공시 • May 13Formycon AG Provides Earnings Guidance for the Year 2025Formycon AG provided earnings guidance for the year 2025. The company expects Revenue to be €55.0 million to €65.0 million.Price Target Changed • Mar 31Price target decreased by 8.4% to €49.56Down from €54.11, the current price target is an average from 9 analysts. New target price is 116% above last closing price of €22.90. Stock is down 51% over the past year. The company is forecast to post a net loss per share of €1.25 next year compared to a net loss per share of €7.18 last year.Reported Earnings • Mar 30Full year 2024 earnings released: €7.19 loss per share (vs €4.76 profit in FY 2023)Full year 2024 results: €7.19 loss per share (down from €4.76 profit in FY 2023). Revenue: €69.7m (down 10% from FY 2023). Net loss: €125.7m (down 266% from profit in FY 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.공시 • Mar 28Formycon AG Provides Earnings Guidance for the Year 2025Formycon AG provided earnings guidance for the year 2025. For the year, the company expected revenue to be EUR 55.0 million to EUR 65.0 million.Major Estimate Revision • Mar 16Consensus EPS estimates upgraded to €2.88 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €60.5m to €59.5m. 2024 losses expected to reduce from -€3.22 to -€2.88 per share. Biotechs industry in Germany expected to see average net income growth of 11% next year. Consensus price target down from €60.44 to €54.11. Share price rose 6.8% to €27.60 over the past week.Price Target Changed • Mar 10Price target decreased by 10% to €54.11Down from €60.44, the current price target is an average from 9 analysts. New target price is 115% above last closing price of €25.15. Stock is down 48% over the past year. The company is forecast to post a net loss per share of €3.21 compared to earnings per share of €4.76 last year.Major Estimate Revision • Mar 05Consensus EPS estimates upgraded to €2.87 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€3.22 to -€2.87 per share. Revenue forecast unchanged from €59.8m at last update. Biotechs industry in Germany expected to see average net income growth of 16% next year. Consensus price target down from €60.44 to €58.67. Share price fell 4.3% to €26.50 over the past week.공시 • Mar 04Fresenius Kabi Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi®? (Ustekinumab-Aauz)Fresenius Kabi and Formycon AG announced that the ustekinumab biosimilarOtulfi®? (ustekinumab-aauz) developed by Formycon AG, is now available in the United States. The development and commercialization of the ustekinumib biosimilar is the first biosimilar product launched in the U.S. from the partnership between Fresenius and Formycon AG. The drug received FDA approval in September 2024. Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. The FDA approval of Otulfi (ustekinumab -aauz) was based on a thorough evaluation of a comprehensive data package including analytical, pre-clinical, clinical and manufacturing data. Otulfi was approved for both subcutaneous and intravenous formulations which will offer a comprehensive, alternative treatment solution for health care professionals and patients treated with Otulfi in the U.S. Otulfi (ustek in the U.S. is the fourth Fresenius biosimilar commercialized in the U.S., following the approvals and launches of Idacio®? (adalimumab-aacf), Tyenne®? (tocilizumab-aazg) and Stimufend®? (pegfilgrastim-fpgk). Serious infections requiring hospitalization, or otherwise clinically significant infections, reported in clinical trials included the following: Plaque psoriasis: diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, urinary tract infections; Malignancies were reported among subjects who received ustekinumab in clinical trials. Two cases of posterior reversible encephalopathy syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported in clinical trials. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients' nutritional status - notably as the only corporation offering both product groups. With Vision 2026, as part of the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders - shaping the future of health care. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, have been approved by the FDA, EMA, and MHRA; Future results could differ materially from those described in the U.S.Major Estimate Revision • Feb 19Consensus EPS estimates fall by 252%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -€0.483 to -€1.70 per share. Revenue forecast unchanged at €60.5m. Biotechs industry in Germany expected to see average net income growth of 16% next year. Consensus price target down from €87.22 to €72.89. Share price fell 41% to €29.90 over the past week.Price Target Changed • Feb 18Price target decreased by 15% to €74.25Down from €87.00, the current price target is an average from 8 analysts. New target price is 124% above last closing price of €33.20. Stock is down 38% over the past year. The company is forecast to post a net loss per share of €0.89 compared to earnings per share of €4.76 last year.New Risk • Feb 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 5.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (5.7% average weekly change). High level of non-cash earnings (27% accrual ratio).Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 38%After last week's 38% share price decline to €32.60, the stock trades at a forward P/E ratio of 781x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 32% over the past three years.공시 • Feb 17Formycon AG Announces Decision on Phase III Trial with FYB206 and Provides Update on Potential Need to Adjust the Valuation of FYB202 and FYB201Formycon AG has decided to prematurely terminate the Phase III trial (‘Lotus’) for its biosimilar candidate Fiscal Year B206. Based on an intensive scientific dialogue with the U.S. Food and Drug Administration (FDA), the Executive Board, after careful consideration, has concluded that the continuation of the study is no longer necessary for the development and approval of Fiscal Year B206 in the U.S. The therapeutic comparability of Fiscal Year B206 with the reference drug Keytruda3 can be sufficiently demonstrated using data from the ongoing parallel study in the melanoma indication (‘Dahlia’), combined with a comprehensive analytical program. According to preliminary estimates, discontinuing the Phase III trial could lead to investment savings in the high double-digit million range over the next few years, positively impacting the Company’s cash flow statement and liquidity. In coordination with commercialization partner Fresenius Kabi AG, as part of the imminent market launch of Fiscal Year B202/Otulfi in the U.S., Formycon anticipates that the valuation model and balance sheet measurement for Fiscal Year B202 will need to be reviewed and adjusted due to an emerging, significantly higher-than-expected price discount for biosimilars. Based on preliminary calculations, Formycon currently expects a non-cash impairment requirement in the high double-digit to low triple-digit million range. Due to the increasing price discounts among ranibizumab providers in the U.S., Bioeq AG, the exclusive license holder of Fiscal Year B201/CIMERLI, is currently in discussions with its commercialization partner Sandoz AG regarding the future commercialization strategy for Fiscal Year B201/CIMERLI in the U.S. Based on the status of these discussions, Formycon currently expects that the commercialization of Fiscal Year B201/CIMERLI will likely be temporarily paused. This would result in an extraordinary adjustment to the valuation model and the balance sheet measurement for Fiscal Year B201, as well as the stake in Bioeq AG, amounting to a high single-digit to low double-digit non-cash million figure for the 2024 financial year. In this context, Bioeq AG is exploring alternative commercialization strategies for the U.S. Formycon will provide updates on further developments in due course.공시 • Jan 21Formycon Receives EU Approval for FYB203 (Aflibercept), A Biosimilar to Eylea, Under the Brand Names Ahzantive and BaiamaFormycon AG received EU approval for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names AHZANTIVE and Baiama and Baiama. In mid-January 2025, Formycon and Teva Pharmaceuticals International GmbH (Teva) signed a licensing agreement for the semi-exclusive commercialization of FYB203 across major parts of Europe and Israel. Concurrently, Formycon has concluded an agreement with Teva for product supply. FYB203 was already approved by the U.S. Food and Drug Administration (FDA) in June 2024. Eylea is a registered trademark of Regeneron Pharmaceuticals Inc. AHZANTIVE is a registered trademark the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees.새로운 내러티브 • Jan 18Expected Launches Of Stelara And Keytruda Biosimilars Will Strengthen Future Pipeline The launch of biosimilars and strategic focus on high-growth areas indicate strong future revenue and earnings potential for Formycon. 공시 • Jan 16Formycon AG and Fresenius Kabi Announce MHRA Approval for FYB202/Otulfi (Ustekinumab), Biosimilar to StelaraFormycon AG and its commercialization partner Fresenius Kabi announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved FYB202/Otulfi (ustekinumab), a biosimilar to Stelara, for the treatment of moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. The U.S. Food and Drug Administration (FDA) as well as the European Commission had already granted marketing authorization for FYB202 in September 2024, followed by Health Canada’s approval end of December 2024. In February 2023, Formycon and Fresenius Kabi had entered into a global license agreement providing Fresenius Kabi with commercialization rights of FYB202 in key global markets, including the UK. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role in inflammatory and immune responses. The approval is based on a thorough evaluation of a comprehensive data package including analytical, pre-clinical, clinical and manufacturing data. FYB202 demonstrated comparable efficacy, safety and pharmacokinetics to the reference drug Stelara in patients with moderate to severe psoriasis vulgaris (plaque psoriasis).Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €62.70, the stock trades at a forward P/E ratio of 1503x. Average trailing P/E is 28x in the Biotechs industry in Europe. Total returns to shareholders of 29% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €45.24 per share.Buy Or Sell Opportunity • Jan 07Now 32% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to €59.50. The fair value is estimated to be €45.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 25% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.공시 • Jan 02+ 2 more updatesFormycon AG to Report Q1, 2025 Results on May 15, 2025Formycon AG announced that they will report Q1, 2025 results on May 15, 2025Major Estimate Revision • Dec 12Consensus EPS estimates upgraded to €0.48 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€0.545 to -€0.483 per share. Revenue forecast steady at €60.4m. Biotechs industry in Germany expected to see average net income growth of 26% next year. Consensus price target of €86.56 unchanged from last update. Share price rose 4.1% to €53.20 over the past week.Major Estimate Revision • Nov 29Consensus EPS estimates upgraded to €0.56 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€0.664 to -€0.555 per share. Revenue forecast steady at €60.3m. Biotechs industry in Germany expected to see average net income growth of 28% next year. Consensus price target of €86.56 unchanged from last update. Share price rose 6.6% to €49.95 over the past week.공시 • Nov 15Formycon AG Appoints Colin Bond as DirectorIn accordance with paragraph 6.4.9 R of the UK Listing Rules, BioPharma Credit PLC, has been informed that Colin Bond, Non-executive Director of the Company, has been appointed as a director of Formycon AG with effect from 1 October 2024.공시 • Oct 01Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)Fresenius Kabi and Formycon AG announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Otulfi (ustekinumab-aauz), its ustekinumab biosimilar referencing Stelara(ustekinumab). Otulfi is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. Fresenius Kabi is further continuing its momentum, striving at expanding its strong Biopharma platform, which is a substantial cornerstone of #FutureFresenius. In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role in inflammatory and immune responses. The FDA approval of Otulfi (ustekinumab-aauz) is based on a thorough evaluation of a comprehensive data package including analytical, pre-clinical, clinical and manufacturing data. Otulfi demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference drug Stelara in patients with moderate to severe psoriasis vulgaris (plaque psoriasis). Otulfi was approved for both subcutaneous and intravenous formulations which will offer a comprehensive, alternative treatment solution for health care professionals and patients treated with ustekinumab in the U.S. Otulfi™ is contraindicated in patients with significant hypersensitivity to ustekinumab or to any of the excipients. Otulfi (ustekinumab-aauz) is Fresenius Kabi’s fourth biosimilar granted a marketing authorization in the U.S., following previous approvals of its commercially available biosimilars Idacio (adalimumab-aacf), Tyenne (tocilizumab-aazg) and Stimufend (pegfilgrastim-fpgk). Fresenius Kabi’s growing pipeline of autoimmune and oncology biosimilars has several molecules in early and late-stage development.Major Estimate Revision • Aug 29Consensus EPS estimates upgraded to €0.70 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€0.958 to -€0.698 per share. Revenue forecast steady at €60.5m. Biotechs industry in Germany expected to see average net income growth of 6.3% next year. Consensus price target broadly unchanged at €84.78. Share price was steady at €51.70 over the past week.Major Estimate Revision • Aug 21Consensus EPS estimates upgraded to €0.96 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€1.08 to -€0.958 per share. Revenue forecast steady at €60.0m. Biotechs industry in Germany expected to see average net income growth of 6.8% next year. Consensus price target broadly unchanged at €86.33. Share price fell 2.9% to €49.40 over the past week.Reported Earnings • Aug 18First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023)First half 2024 results: €0.58 loss per share (down from €0.11 profit in 1H 2023). Revenue: €26.9m (down 39% from 1H 2023). Net loss: €10.1m (down €11.9m from profit in 1H 2023). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Aug 17Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €49.20. The fair value is estimated to be €61.92, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 33% per annum. Earnings are also forecast to grow by 31% per annum over the same time period.공시 • Aug 06Formycon AG to Report First Half, 2024 Results on Aug 13, 2024Formycon AG announced that they will report first half, 2024 results on Aug 13, 2024New Risk • Aug 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding).분석 기사 • Jul 20A Look At The Fair Value Of Formycon AG (ETR:FYB)Key Insights Using the 2 Stage Free Cash Flow to Equity, Formycon fair value estimate is €60.63 Current share price of...Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €55.80, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 28x in the Biotechs industry in Europe. Total loss to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €55.29 per share.Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €49.85, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 18% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €26.93 per share.분석 기사 • May 29Formycon AG's (ETR:FYB) Prospects Need A Boost To Lift SharesFormycon AG's ( ETR:FYB ) price-to-earnings (or "P/E") ratio of 10.3x might make it look like a buy right now compared...Price Target Changed • May 13Price target decreased by 8.7% to €87.00Down from €95.25, the current price target is an average from 6 analysts. New target price is 104% above last closing price of €42.75. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €1.05 compared to earnings per share of €4.76 last year.분석 기사 • May 03We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its ProfitabilityFormycon AG ( ETR:FYB ) recently released a strong earnings report, and the market responded by raising the share...공시 • May 03Formycon AG to Report Q1, 2024 Results on May 08, 2024Formycon AG announced that they will report Q1, 2024 results on May 08, 2024Reported Earnings • Apr 25Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)Full year 2023 results: EPS: €4.76 (up from €2.62 in FY 2022). Revenue: €77.7m (up 83% from FY 2022). Net income: €75.8m (up 111% from FY 2022). Profit margin: 98% (up from 85% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.공시 • Apr 13Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024Formycon AG announced that they will report fiscal year 2023 final results on Apr 25, 2024Price Target Changed • Apr 11Price target decreased by 12% to €96.25Down from €109, the current price target is an average from 4 analysts. New target price is 109% above last closing price of €45.95. Stock is down 31% over the past year. The company is forecast to post earnings per share of €3.38 for next year compared to €2.62 last year.New Risk • Apr 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.Price Target Changed • Jan 31Price target decreased by 7.9% to €103Down from €112, the current price target is an average from 5 analysts. New target price is 101% above last closing price of €51.30. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.023 for next year compared to €2.62 last year.공시 • Jan 30Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million. Security Name: Bearer Shares Security Type: Common Stock Securities Offered: 1,603,877 Price\Range: €51.65 Transaction Features: Subsequent Direct Listing분석 기사 • Jan 19Some Confidence Is Lacking In Formycon AG's (ETR:FYB) P/SWith a price-to-sales (or "P/S") ratio of 11.4x Formycon AG ( ETR:FYB ) may be sending bearish signals at the moment...분석 기사 • Dec 23We Think Formycon (ETR:FYB) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (45% increase in shares outstanding).분석 기사 • Sep 26Formycon AG's (ETR:FYB) Share Price Not Quite Adding UpYou may think that with a price-to-sales (or "P/S") ratio of 12.8x Formycon AG ( ETR:FYB ) is a stock to avoid...Reported Earnings • Sep 08First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)First half 2023 results: EPS: €0.11 (down from €6.51 in 1H 2022). Revenue: €43.8m (up 148% from 1H 2022). Net income: €1.80m (down 98% from 1H 2022). Profit margin: 4.1% (down from 454% in 1H 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.공시 • Aug 24Formycon AG to Report First Half, 2023 Results on Aug 30, 2023Formycon AG announced that they will report first half, 2023 results on Aug 30, 2023Major Estimate Revision • Aug 09Consensus EPS estimates fall by 146%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €81.3m to €78.3m. Losses expected to increase from €0.51 per share to €1.26. Biotechs industry in Germany expected to see average net income growth of 6.1% next year. Consensus price target of €116 unchanged from last update. Share price was steady at €67.10 over the past week.Price Target Changed • Jul 24Price target decreased by 8.6% to €116Down from €126, the current price target is an average from 2 analysts. New target price is 82% above last closing price of €63.50. Stock is down 18% over the past year. The company is forecast to post a net loss per share of €0.49 compared to earnings per share of €2.62 last year.공시 • Jun 29Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)Formycon AG nd its license partner Klinge Biopharma GmbH (“Klinge“) announce that the biologics license application (BLA) for FYB203, a biosimilar candidate for Eylea®1 (Active ingredient: Aflibercept) has been submitted to the U.S. Food and Drug Administration („FDA“) in line with the initial schedule. Within 60 days after submission, FDA is expected to decide on whether to accept and to further review the BLA (“file acceptance”). Eylea® is used in the treatment of neovascular age-related macular degeneration (“nAMD”) and other severe retinal diseases. It inhibits vascular endothelial growth factor (“VEGF”), which is responsible for the excessive formation of blood vessels in the retina. With global sales of around USD 9.6 billion[i] Eylea® is currently the top-selling drug in this therapeutic area.Valuation Update With 7 Day Price Move • May 18Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €77.60, the stock trades at a trailing P/E ratio of 34.6x. Average forward P/E is 32x in the Biotechs industry in Europe. Total returns to shareholders of 209% over the past three years.Reported Earnings • Apr 30Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2022 results: EPS: €2.62 (up from €1.22 loss in FY 2021). Revenue: €42.5m (up 15% from FY 2021). Net income: €36.0m (up €49.5m from FY 2021). Profit margin: 85% (up from net loss in FY 2021). The move to profitability was primarily driven by lower expenses. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates by 114%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.공시 • Feb 03Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million. Security Name: Shares Security Type: Common Stock Securities Offered: 910,000 Price\Range: €77 Transaction Features: Rule 144A; Subsequent Direct ListingPrice Target Changed • Nov 16Price target increased to €126Up from €97.67, the current price target is an average from 3 analysts. New target price is 70% above last closing price of €74.30. Stock is up 50% over the past year. The company is forecast to post earnings per share of €3.19 next year compared to a net loss per share of €1.22 last year.분석 기사 • Nov 05We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) EarningsThe recent earnings posted by Formycon AG ( ETR:FYB ) were solid, but the stock didn't move as much as we expected. We...Reported Earnings • Oct 31First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)First half 2022 results: EPS: €6.51 (up from €0.92 loss in 1H 2021). Revenue: €17.6m (down 13% from 1H 2021). Net income: €80.0m (up €90.2m from 1H 2021). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.공시 • Sep 20Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)Formycon AG announced details of a previously undisclosed project in its development pipeline. FYB206 is a biosimilar candidate for Keytruda® (pembrolizumab) and the development is at an advanced preclinical stage. In addition to biosimilars in the field of ophthalmology (FYB201/FYB203), immunology (FYB202) and two further yet unpublished biosimilar candidates (FYB208/FYB209), Formycon is expanding its therapeutic range with FYB206 to the rapidly growing field of immuno-oncology. The active ingredient pembrolizumab is a humanized monoclonal antibody that belongs to the group of immune checkpoint inhibitors and is established in the treatment of a variety of tumors. Pembrolizumab binds to the PD-1 receptor and specifically blocks the interaction between PD-1 and its ligand PD-L1. This helps the immune system activate the body's own cellular anti-tumor immune response and kill e.g. melanoma cells. Since 2015, Keytruda® has been established for the treatment of advanced melanoma, lung and other types of carcinoma. In 2021, the reference market for Keytruda® was reported at a size of more than USD 17 billion worldwide.[i] Expert analyses predict that Keytruda® will become the world's top-selling drug in 2023, with annual revenue potential expected to be well over USD 20 billion as early as 2025. The development and commercialization rights for FYB206 are fully owned by Formycon. Important IP has already been created and patent applications have been filed, with data from the development of alternative formulations. Following convincing results from the extensive analytical protein characterization as well as significant progress in the development of the manufacturing process, a comprehensive data package is currently being compiled in order to closely align further program steps in Scientific Advice Meetings with the EMA and FDA in the second half of the year. Adjusting the manufacturing process to commercial scale is planned for the end of 2022. For this purpose, Formycon has already secured GMP manufacturing capacities at a renowned contract manufacturer.Price Target Changed • Sep 19Price target increased to €107Up from €95.67, the current price target is an average from 3 analysts. New target price is 53% above last closing price of €70.30. Stock is up 36% over the past year. The company is forecast to post earnings per share of €3.05 next year compared to a net loss per share of €1.22 last year.Major Estimate Revision • Sep 07Consensus forecasts updatedThe consensus outlook for 2022 has been updated. Forecast profits in 2022 with EPS up from -€1.09 to €3.05 per share. Revenue forecast unchanged from last update at €41.9m. Biotechs industry in Germany expected to see average net income growth of 8.6% next year. Consensus price target of €97.67 unchanged from last update. Share price fell 4.4% to €72.20 over the past week.분석 기사 • Sep 04We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...공시 • Aug 29Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)Formycon AG (“Formycon”), Polpharma Biologics Group BV (“Polpharma Biologics”) and Bioeq AG (“Bioeq”) jointly announce that the European Commission (“EC”) has granted marketing authorization (“MA”) for Ranivisio (Ranivisio - Ranibizumab), a biosimilar to Lucentis (ranibizumab-injection), for the treatment for several serious retinal diseases in the European Union. EC approval follows a positive opinion issued in June 2022 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and is applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein. Ranivisio is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), the treatment of visual impairment due to diabetic macular oedema (DME) or choroidal neovascularization (CNV), the treatment of proliferative diabetic retinopathy (PDR), as well as the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). FYB201/Ranivisio was developed by Bioeq, a Joint Venture between Formycon and Polpharma Biologics. Mid 2021, Teva Pharmaceutical Industries Ltd. (“Teva”) entered into a strategic partnership for the exclusive commercialization of FYB201 in Europe and selected other countries. Commercial launches across Europe are planned over the coming year, and the treatment is already available in the UK under the tradename Ongavia3, following its approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022. The EU-approval is based on the totality of evidence including analytical, nonclinical, clinical and manufacturing data. In a randomized, double-masked, parallel group, multicenter phase III study (COLUMBUS-AMD) it was shown that Ranivisio is highly similar to the reference product Lucentis in terms of comparable efficacy, safety, pharmacokinetics and immunogenicity in patients with age-related neovascular (wet) macular degeneration. AMD is caused by excessive growth of blood vessels in the retina. Ranibizumab inhibits vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of these blood vessels in the retina. In developed countries AMD is the most common cause of severe visual impairment or blindness and it is estimated that up to 77 million Europeans will be affected by 2050. The consequences of AMD carry a significant burden for healthcare systems and societies as the increasing incidence of the condition is expected to absorb considerable amounts of healthcare resources and funds across the EU.공시 • Aug 27Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to LucentisFormycon AG announced that the European Commission (EC) has granted marketing authorization (MA) for Ranivisio®, a biosimilar to Lucentis® (ranibizumab-injection) for medical use in the European Union (EU). FYB201/Ranivisio® was developed by Bioeq, a Joint Venture between Formycon and Polpharma Biologics. Mid 2021, Teva Pharmaceutical Industries Ltd. (Teva) entered into a strategic partnership for the exclusive commercialization of FYB201 under the brand name Ranivisio® in the EU. The commercial launch of Ranivisio® in the EU is planned as soon as possible. The European Commission now followed the positive opinion issued by the Committee for Medicinal Products for Human Use ("CHMP") in June 2022 and approved Ranivisio® for the treatment of neovascular (wet) age-related macular degeneration (nAMD), the treatment of visual impairment due to diabetic macular oedema (DME) or choroidal neovascularization (CNV), the treatment of proliferative diabetic retinopathy (PDR) as well as the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). The EU-approval is based on a totality of evidence including analytical, nonclinical, clinical and manufacturing data. In a randomized, double-masked, parallel group, multicenter phase III study (COLUMBUS-AMD) it was shown that Ranivisio® is highly similar to the reference product Lucentis® in terms of comparable efficacy, safety, pharmacokinetics and immunogenicity in patients with age-related neovascular (wet) macular degeneration.공시 • Aug 16Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III StudyFormycon AG reported positive preliminary efficacy and safety data from VESPUCCI Phase III clinical trial for FYB202, its proposed biosimilar version of Stelara-(Ustekinumab). The multi-center, randomized, double-blinded, comparative clinical study met the primary efficacy endpoint, demonstrating comparable efficacy between FYB202 and the reference medicine Stelara- in patients with moderate to severe psoriasis vulgaris (plaque psoriasis). This is the most common form of psoriasis, accounting for 80% to 90% of all cases. The primary endpoint of the comparative global Phase III study measures the % improvement of the Psoriasis Area and Severity Index (PASI) at 12 weeks from baseline. The values obtained for FYB202 and reference product are within the relevant equivalence limits. In addition, to date, no clinically meaningful differences in safety and immunogenicity have been observed. The extended Phase I pharmacokinetics study has commenced. Recruitment is evolving according to plan and a substantial number of subjects has already been enrolled in the study. The active ingredient ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23. Since 2009, Stelara- has been used to treat various severe inflammatory conditions such as moderate to severe psoriasis as well as psoriatic arthritis. Its approved indications were expanded to chronic inflammatory bowel diseases like treatment of Crohn's disease (2016) and ulcerative colitis (2019). Stelara- achieved a global sales volume of over USD 9 billion in 2021. As a result of the transaction with ATHOS KG, which was successfully concluded in the first half of 2022, the global commercialization rights to FYB202 are held in full by Formycon AG (prior to the transaction 24.9% co-ownership share).공시 • Aug 04Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2Formycon AG announced that the U.S. Food and Drug Administration ("FDA") has approved CIMERLIT (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis- (ranibizumab injection). FYB201 was developed by Bioeq AG, a Joint Venture between Formycon AG and Polpharma Biologics Group BV. End of the year 2019, Coherus BioSciences Inc. ("Coherus") entered into a license agreement for the exclusive commercialization of FYB201 under the brand name CIMERLIT in the United States of America ("U.S."). The commercial launch of CIMERLIT, in both 0.3mg and 0.5mg dosages, in the U.S. by Coherus, is planned for early October 2022. CIMERLIT obtained approval from FDA for the treatment of Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema following Retinal Vein Occlusion (RVO) and Myopic Choroidal Neovascularization (mCNV). CIMERLIT is the first and only interchangeable biosimilar with an exclusivity for 12 month after market launch, that is indicated for the treatment of all five Lucentis- indications and as such is a new medical option for patients with serious retinal diseases. FDA-approval and interchangeability designation are based on a totality of evidence including analytical, nonclinical, clinical and manufacturing data. Efficacy, safety, pharmacokinetics and immunogenicity of CIMERLIT were found to be comparable to the reference drug Lucentis- in patients with Age-Related Neovascular (wet) Macular Degeneration (nAMD).분석 기사 • Jul 13Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)Shareholders in Formycon AG ( ETR:FYB ) may be thrilled to learn that the analysts have just delivered a major upgrade...Major Estimate Revision • Jul 12Consensus revenue estimates increase by 13%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from €32.9m to €37.1m. Forecast losses expected to reduce from -€1.44 to -€1.09 per share. Biotechs industry in Germany expected to see average net income growth of 11% next year. Consensus price target up from €93.00 to €95.67. Share price fell 3.0% to €74.00 over the past week.공시 • Jul 02Formycon AG Announces Supervisory Board and Executive ChangesFormycon AG at it's AGM elected Dr. Thomas Strüngmann to the Supervisory Board and Dr. Andreas Seidl, the future Chief Scientific Officer (CSO), who was appointed to the Management Board by the Supervisory Board effective July 01, 2022.공시 • Jun 25Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMAFormycon AG and its licensing partner Bioeq AG announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") issued a positive opinion for FYB201, a biosimilar to Lucentis. FYB201 has thus been recommended for approval in the European Union (EU) for the treatment of patients with age-related neovascular (wet) macular degeneration (AMD) and other serious ocular diseases such as diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), macular edema due to retinal vein occlusion (branch RVO or central RVO) and choroidal neovascularization (CNV). The CHMP recommendation is based on an in-depth evaluation of a comprehensive set of data for comparative analytical characterization and commercial-scale manufacturing. In a randomized, double-blind, multicenter, parallel-group Phase III study, FYB201 also demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference drug Lucentis- (ranibizumab) in patients with age-related neovascular (wet) macular degeneration.Within the approval process, the CHMP's favorable opinion represents an important regulatory step towards the approval of FYB201 in the European Union. The CHMP's scientific assessment report forms the basis for the European Commission's decision to grant a central marketing authorization, which is expected at the end of August.분석 기사 • Jun 02Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimatesThe latest analyst coverage could presage a bad day for Formycon AG ( ETR:FYB ), with the analysts making...Major Estimate Revision • Jun 01Consensus revenue estimates fall by 17%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €39.4m to €32.9m. Forecast losses increased from -€0.97 to -€1.44 per share. Biotechs industry in Germany expected to see average net income growth of 10% next year. Consensus price target up from €91.00 to €93.00. Share price rose 4.1% to €74.50 over the past week.분석 기사 • May 23Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • May 22Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: €1.22 loss per share (down from €0.54 loss in FY 2020). Revenue: €37.0m (up 8.0% from FY 2020). Net loss: €13.5m (loss widened 127% from FY 2020). Products in clinical trials Phase III: 2 Revenue missed analyst estimates by 9.5%. Earnings per share (EPS) also missed analyst estimates by 2.6%. Over the next year, revenue is forecast to grow 6.6%, compared to a 29% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 132 percentage points per year, which is a significant difference in performance.매출 및 비용 세부 내역Formycon가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이XTRA:FYB 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 2544-65201330 Sep 2548-165211330 Jun 2552-170211531 Mar 2561-148211631 Dec 2470-126211730 Sep 245816181530 Jun 246164181431 Mar 246970171131 Dec 23787615930 Sep 237317131230 Jun 2369-42121431 Mar 2356-3121631 Dec 224236121730 Sep 223857111530 Jun 223477101331 Mar 22353281531 Dec 2137-1371730 Sep 2137-1542330 Jun 2138-1581231 Mar 2136-119631 Dec 2034-76930 Sep 2033-410030 Jun 2032-310031 Mar 2033-310031 Dec 1933-29030 Sep 1934-29030 Jun 1936-18031 Mar 193938031 Dec 184378030 Sep 184487030 Jun 184597031 Mar 183747031 Dec 1729-26030 Sep 1724-46030 Jun 1719-66031 Mar 1719-55031 Dec 1620-45030 Sep 1618-35030 Jun 1616-25031 Mar 1616-14031 Dec 151714030 Sep 151904030 Jun 1522030양질의 수익: FYB 은(는) 현재 수익성이 없습니다.이익 마진 증가: FYB는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: FYB은 수익성이 없으며 지난 5년 동안 손실이 연평균 42.8% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 FYB의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: FYB은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(45%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: FYB는 현재 수익성이 없으므로 자본 수익률이 음수(-16.21%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 11:18종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Formycon AG는 12명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gerhard OrgonasBerenbergBenjamin ThielmannBerenbergSimon ScholesFirst Berlin Equity Research GmbH9명의 분석가 더 보기
Reported Earnings • Apr 24Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: €3.66 loss per share (improved from €7.19 loss in FY 2024). Revenue: €44.5m (down 36% from FY 2024). Net loss: €64.7m (loss narrowed 49% from FY 2024). Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 81%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
공시 • Apr 16Formycon AG to Report Fiscal Year 2025 Results on Apr 22, 2026Formycon AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 22, 2026
공시 • Dec 30+ 3 more updatesFormycon AG to Report Fiscal Year 2025 Results on Mar 26, 2026Formycon AG announced that they will report fiscal year 2025 results on Mar 26, 2026
Reported Earnings • Aug 19First half 2025 earnings released: €3.07 loss per share (vs €0.58 loss in 1H 2024)First half 2025 results: €3.07 loss per share (further deteriorated from €0.58 loss in 1H 2024). Revenue: €9.00m (down 67% from 1H 2024). Net loss: €54.2m (loss widened 437% from 1H 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 30Full year 2024 earnings released: €7.19 loss per share (vs €4.76 profit in FY 2023)Full year 2024 results: €7.19 loss per share (down from €4.76 profit in FY 2023). Revenue: €69.7m (down 10% from FY 2023). Net loss: €125.7m (down 266% from profit in FY 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.
공시 • Jan 02+ 2 more updatesFormycon AG to Report Q1, 2025 Results on May 15, 2025Formycon AG announced that they will report Q1, 2025 results on May 15, 2025
공시 • May 05Formycon AG, Annual General Meeting, Jun 10, 2026Formycon AG, Annual General Meeting, Jun 10, 2026, at 10:00 W. Europe Standard Time.
내러티브 업데이트 • Apr 30FYB: Future Earnings Guidance And Biosimilar Progress Will Support Bullish OutlookAnalysts have raised their price target for Formycon from €35.69 to €40.14, citing updated assumptions around revenue growth, profit margins, and the P/E multiple used in their models. What's in the News Formycon issued earnings guidance for 2026, with the group expecting revenue in a range of €60.0 million to €70.0 million.
Reported Earnings • Apr 24Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: €3.66 loss per share (improved from €7.19 loss in FY 2024). Revenue: €44.5m (down 36% from FY 2024). Net loss: €64.7m (loss narrowed 49% from FY 2024). Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 81%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
공시 • Apr 16Formycon AG to Report Fiscal Year 2025 Results on Apr 22, 2026Formycon AG announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 22, 2026
New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Major Estimate Revision • Mar 08Consensus EPS estimates fall by 15%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.81 to -€2.09 per share. Revenue forecast of €55.2m unchanged since last update. Biotechs industry in Germany expected to see average net income growth of 16% next year. Consensus price target down from €41.86 to €40.71. Share price fell 14% to €19.74 over the past week.
새로운 내러티브 • Feb 09Regulatory Tailwinds And Biosimilar Royalties Will Slowly Overcome Concentrated Pipeline RisksCatalysts About Formycon Formycon develops and commercializes biosimilar medicines in collaboration with partners across global markets. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Jan 24Regulatory Tailwinds And Biosimilar Pipeline Will Reshape Long Term Earnings PowerCatalysts About Formycon Formycon develops and commercializes biosimilar medicines, focusing on high-value biologics in ophthalmology, immunology and oncology. What are the underlying business or industry changes driving this perspective?
Buy Or Sell Opportunity • Jan 15Now 21% undervaluedOver the last 90 days, the stock has risen 3.9% to €24.20. The fair value is estimated to be €30.70, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 61% in a year. Earnings are forecast to grow by 91% in the next year.
공시 • Dec 30+ 3 more updatesFormycon AG to Report Fiscal Year 2025 Results on Mar 26, 2026Formycon AG announced that they will report fiscal year 2025 results on Mar 26, 2026
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
New Risk • Nov 20New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €170m Forecast net loss in 2 years: €560k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company.
Major Estimate Revision • Nov 15Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from €54.2m to €54.9m. EPS estimate increased from -€2.16 per share to -€1.91 per share. Biotechs industry in Germany expected to see average net income growth of 22% next year. Consensus price target of €43.63 unchanged from last update. Share price rose 7.5% to €20.75 over the past week.
Major Estimate Revision • Aug 31Consensus EPS estimates fall by 12%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.88 to -€2.11 per share. Revenue forecast unchanged at €54.9m. Biotechs industry in Germany expected to see average net income growth of 15% next year. Consensus price target of €43.75 unchanged from last update. Share price was steady at €24.15 over the past week.
Major Estimate Revision • Aug 20Consensus EPS estimates fall by 12%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €56.4m to €54.9m. Losses expected to increase from €1.69 per share to €1.90. Biotechs industry in Germany expected to see average net income growth of 16% next year. Consensus price target broadly unchanged at €43.75. Share price was steady at €24.60 over the past week.
Reported Earnings • Aug 19First half 2025 earnings released: €3.07 loss per share (vs €0.58 loss in 1H 2024)First half 2025 results: €3.07 loss per share (further deteriorated from €0.58 loss in 1H 2024). Revenue: €9.00m (down 67% from 1H 2024). Net loss: €54.2m (loss widened 437% from 1H 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Aug 05Consensus EPS estimates fall by 21%The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -€1.40 to -€1.69 per share. Revenue forecast unchanged at €56.4m. Biotechs industry in Germany expected to see average net income growth of 16% next year. Consensus price target broadly unchanged at €44.25. Share price fell 14% to €25.40 over the past week.
공시 • Jul 11Formycon AG Completes Patient Enrollment for the Clinical Development of Its Keytruda®? Biosimilar Candidate FYB206Formycon AG announced that the patient enrollment for the clinical PK study Dahlia has been successfully completed with a total of 96 participants (Last Patient-In). The Dahlia study, which was launched in June 2024 in selected Southeastern and Eastern European study centers, compares the pharmacokinetics, safety and tolerability of FYB206 with the immuno-oncology blockbuster drug Keytruda®?2. At the end of 2024, Formycon submitted a streamlined clinical strategy to the U.S. Food and Drug Administration (FDA) with the intention to demonstrate the therapeutic comparability of FYB206 With the reference drug Keytruda®? based on comprehensive analytical data and data from the PK study (Dahlia). Following a positive response from the FDA, the company decided in February 2025 to discontinue recruitment for the already-started Phase III trial. This decision accelerates the development of the biosimilar and at the same time significantly reduces the related investments over the coming years. The treatment of patients already enrolled in the Phase III trial has subsequently been continued with the locally available Keytruda®? outside the trial. With streamlined clinical development program for FYB206, have secured a leading role among the developers of a pembrolizumab biosimilar. This is further underlined by the efficient and reliable execution of the Dahlia PK study. The first patients in the Dahlia trial have already completed all 17 treatment cycles. therefore currently expect to receive the results of the study endpoint in the first quarter of 2026.
Price Target Changed • Jul 01Price target decreased by 11% to €44.13Down from €49.33, the current price target is an average from 8 analysts. New target price is 60% above last closing price of €27.55. Stock is down 50% over the past year. The company is forecast to post a net loss per share of €1.37 next year compared to a net loss per share of €7.18 last year.
공시 • Jun 20Formycon Ag Elects Graham Keith Dixon as A New Member of the Supervisory BoardFormycon AG announced that Graham Keith Dixon elected as a new member of the Supervisory Board.
공시 • May 13Formycon AG Provides Earnings Guidance for the Year 2025Formycon AG provided earnings guidance for the year 2025. The company expects Revenue to be €55.0 million to €65.0 million.
Price Target Changed • Mar 31Price target decreased by 8.4% to €49.56Down from €54.11, the current price target is an average from 9 analysts. New target price is 116% above last closing price of €22.90. Stock is down 51% over the past year. The company is forecast to post a net loss per share of €1.25 next year compared to a net loss per share of €7.18 last year.
Reported Earnings • Mar 30Full year 2024 earnings released: €7.19 loss per share (vs €4.76 profit in FY 2023)Full year 2024 results: €7.19 loss per share (down from €4.76 profit in FY 2023). Revenue: €69.7m (down 10% from FY 2023). Net loss: €125.7m (down 266% from profit in FY 2023). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 27% per year, which means it has not declined as severely as earnings.
공시 • Mar 28Formycon AG Provides Earnings Guidance for the Year 2025Formycon AG provided earnings guidance for the year 2025. For the year, the company expected revenue to be EUR 55.0 million to EUR 65.0 million.
Major Estimate Revision • Mar 16Consensus EPS estimates upgraded to €2.88 loss, revenue downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from €60.5m to €59.5m. 2024 losses expected to reduce from -€3.22 to -€2.88 per share. Biotechs industry in Germany expected to see average net income growth of 11% next year. Consensus price target down from €60.44 to €54.11. Share price rose 6.8% to €27.60 over the past week.
Price Target Changed • Mar 10Price target decreased by 10% to €54.11Down from €60.44, the current price target is an average from 9 analysts. New target price is 115% above last closing price of €25.15. Stock is down 48% over the past year. The company is forecast to post a net loss per share of €3.21 compared to earnings per share of €4.76 last year.
Major Estimate Revision • Mar 05Consensus EPS estimates upgraded to €2.87 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€3.22 to -€2.87 per share. Revenue forecast unchanged from €59.8m at last update. Biotechs industry in Germany expected to see average net income growth of 16% next year. Consensus price target down from €60.44 to €58.67. Share price fell 4.3% to €26.50 over the past week.
공시 • Mar 04Fresenius Kabi Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi®? (Ustekinumab-Aauz)Fresenius Kabi and Formycon AG announced that the ustekinumab biosimilarOtulfi®? (ustekinumab-aauz) developed by Formycon AG, is now available in the United States. The development and commercialization of the ustekinumib biosimilar is the first biosimilar product launched in the U.S. from the partnership between Fresenius and Formycon AG. The drug received FDA approval in September 2024. Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. The FDA approval of Otulfi (ustekinumab -aauz) was based on a thorough evaluation of a comprehensive data package including analytical, pre-clinical, clinical and manufacturing data. Otulfi was approved for both subcutaneous and intravenous formulations which will offer a comprehensive, alternative treatment solution for health care professionals and patients treated with Otulfi in the U.S. Otulfi (ustek in the U.S. is the fourth Fresenius biosimilar commercialized in the U.S., following the approvals and launches of Idacio®? (adalimumab-aacf), Tyenne®? (tocilizumab-aazg) and Stimufend®? (pegfilgrastim-fpgk). Serious infections requiring hospitalization, or otherwise clinically significant infections, reported in clinical trials included the following: Plaque psoriasis: diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, urinary tract infections; Malignancies were reported among subjects who received ustekinumab in clinical trials. Two cases of posterior reversible encephalopathy syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported in clinical trials. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients' nutritional status - notably as the only corporation offering both product groups. With Vision 2026, as part of the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders - shaping the future of health care. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, have been approved by the FDA, EMA, and MHRA; Future results could differ materially from those described in the U.S.
Major Estimate Revision • Feb 19Consensus EPS estimates fall by 252%The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -€0.483 to -€1.70 per share. Revenue forecast unchanged at €60.5m. Biotechs industry in Germany expected to see average net income growth of 16% next year. Consensus price target down from €87.22 to €72.89. Share price fell 41% to €29.90 over the past week.
Price Target Changed • Feb 18Price target decreased by 15% to €74.25Down from €87.00, the current price target is an average from 8 analysts. New target price is 124% above last closing price of €33.20. Stock is down 38% over the past year. The company is forecast to post a net loss per share of €0.89 compared to earnings per share of €4.76 last year.
New Risk • Feb 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 5.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (5.7% average weekly change). High level of non-cash earnings (27% accrual ratio).
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment deteriorates as stock falls 38%After last week's 38% share price decline to €32.60, the stock trades at a forward P/E ratio of 781x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 32% over the past three years.
공시 • Feb 17Formycon AG Announces Decision on Phase III Trial with FYB206 and Provides Update on Potential Need to Adjust the Valuation of FYB202 and FYB201Formycon AG has decided to prematurely terminate the Phase III trial (‘Lotus’) for its biosimilar candidate Fiscal Year B206. Based on an intensive scientific dialogue with the U.S. Food and Drug Administration (FDA), the Executive Board, after careful consideration, has concluded that the continuation of the study is no longer necessary for the development and approval of Fiscal Year B206 in the U.S. The therapeutic comparability of Fiscal Year B206 with the reference drug Keytruda3 can be sufficiently demonstrated using data from the ongoing parallel study in the melanoma indication (‘Dahlia’), combined with a comprehensive analytical program. According to preliminary estimates, discontinuing the Phase III trial could lead to investment savings in the high double-digit million range over the next few years, positively impacting the Company’s cash flow statement and liquidity. In coordination with commercialization partner Fresenius Kabi AG, as part of the imminent market launch of Fiscal Year B202/Otulfi in the U.S., Formycon anticipates that the valuation model and balance sheet measurement for Fiscal Year B202 will need to be reviewed and adjusted due to an emerging, significantly higher-than-expected price discount for biosimilars. Based on preliminary calculations, Formycon currently expects a non-cash impairment requirement in the high double-digit to low triple-digit million range. Due to the increasing price discounts among ranibizumab providers in the U.S., Bioeq AG, the exclusive license holder of Fiscal Year B201/CIMERLI, is currently in discussions with its commercialization partner Sandoz AG regarding the future commercialization strategy for Fiscal Year B201/CIMERLI in the U.S. Based on the status of these discussions, Formycon currently expects that the commercialization of Fiscal Year B201/CIMERLI will likely be temporarily paused. This would result in an extraordinary adjustment to the valuation model and the balance sheet measurement for Fiscal Year B201, as well as the stake in Bioeq AG, amounting to a high single-digit to low double-digit non-cash million figure for the 2024 financial year. In this context, Bioeq AG is exploring alternative commercialization strategies for the U.S. Formycon will provide updates on further developments in due course.
공시 • Jan 21Formycon Receives EU Approval for FYB203 (Aflibercept), A Biosimilar to Eylea, Under the Brand Names Ahzantive and BaiamaFormycon AG received EU approval for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names AHZANTIVE and Baiama and Baiama. In mid-January 2025, Formycon and Teva Pharmaceuticals International GmbH (Teva) signed a licensing agreement for the semi-exclusive commercialization of FYB203 across major parts of Europe and Israel. Concurrently, Formycon has concluded an agreement with Teva for product supply. FYB203 was already approved by the U.S. Food and Drug Administration (FDA) in June 2024. Eylea is a registered trademark of Regeneron Pharmaceuticals Inc. AHZANTIVE is a registered trademark the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees.
새로운 내러티브 • Jan 18Expected Launches Of Stelara And Keytruda Biosimilars Will Strengthen Future Pipeline The launch of biosimilars and strategic focus on high-growth areas indicate strong future revenue and earnings potential for Formycon.
공시 • Jan 16Formycon AG and Fresenius Kabi Announce MHRA Approval for FYB202/Otulfi (Ustekinumab), Biosimilar to StelaraFormycon AG and its commercialization partner Fresenius Kabi announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved FYB202/Otulfi (ustekinumab), a biosimilar to Stelara, for the treatment of moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. The U.S. Food and Drug Administration (FDA) as well as the European Commission had already granted marketing authorization for FYB202 in September 2024, followed by Health Canada’s approval end of December 2024. In February 2023, Formycon and Fresenius Kabi had entered into a global license agreement providing Fresenius Kabi with commercialization rights of FYB202 in key global markets, including the UK. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role in inflammatory and immune responses. The approval is based on a thorough evaluation of a comprehensive data package including analytical, pre-clinical, clinical and manufacturing data. FYB202 demonstrated comparable efficacy, safety and pharmacokinetics to the reference drug Stelara in patients with moderate to severe psoriasis vulgaris (plaque psoriasis).
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €62.70, the stock trades at a forward P/E ratio of 1503x. Average trailing P/E is 28x in the Biotechs industry in Europe. Total returns to shareholders of 29% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €45.24 per share.
Buy Or Sell Opportunity • Jan 07Now 32% overvalued after recent price riseOver the last 90 days, the stock has risen 16% to €59.50. The fair value is estimated to be €45.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 25% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
공시 • Jan 02+ 2 more updatesFormycon AG to Report Q1, 2025 Results on May 15, 2025Formycon AG announced that they will report Q1, 2025 results on May 15, 2025
Major Estimate Revision • Dec 12Consensus EPS estimates upgraded to €0.48 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€0.545 to -€0.483 per share. Revenue forecast steady at €60.4m. Biotechs industry in Germany expected to see average net income growth of 26% next year. Consensus price target of €86.56 unchanged from last update. Share price rose 4.1% to €53.20 over the past week.
Major Estimate Revision • Nov 29Consensus EPS estimates upgraded to €0.56 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€0.664 to -€0.555 per share. Revenue forecast steady at €60.3m. Biotechs industry in Germany expected to see average net income growth of 28% next year. Consensus price target of €86.56 unchanged from last update. Share price rose 6.6% to €49.95 over the past week.
공시 • Nov 15Formycon AG Appoints Colin Bond as DirectorIn accordance with paragraph 6.4.9 R of the UK Listing Rules, BioPharma Credit PLC, has been informed that Colin Bond, Non-executive Director of the Company, has been appointed as a director of Formycon AG with effect from 1 October 2024.
공시 • Oct 01Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)Fresenius Kabi and Formycon AG announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Otulfi (ustekinumab-aauz), its ustekinumab biosimilar referencing Stelara(ustekinumab). Otulfi is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. Fresenius Kabi is further continuing its momentum, striving at expanding its strong Biopharma platform, which is a substantial cornerstone of #FutureFresenius. In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role in inflammatory and immune responses. The FDA approval of Otulfi (ustekinumab-aauz) is based on a thorough evaluation of a comprehensive data package including analytical, pre-clinical, clinical and manufacturing data. Otulfi demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference drug Stelara in patients with moderate to severe psoriasis vulgaris (plaque psoriasis). Otulfi was approved for both subcutaneous and intravenous formulations which will offer a comprehensive, alternative treatment solution for health care professionals and patients treated with ustekinumab in the U.S. Otulfi™ is contraindicated in patients with significant hypersensitivity to ustekinumab or to any of the excipients. Otulfi (ustekinumab-aauz) is Fresenius Kabi’s fourth biosimilar granted a marketing authorization in the U.S., following previous approvals of its commercially available biosimilars Idacio (adalimumab-aacf), Tyenne (tocilizumab-aazg) and Stimufend (pegfilgrastim-fpgk). Fresenius Kabi’s growing pipeline of autoimmune and oncology biosimilars has several molecules in early and late-stage development.
Major Estimate Revision • Aug 29Consensus EPS estimates upgraded to €0.70 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€0.958 to -€0.698 per share. Revenue forecast steady at €60.5m. Biotechs industry in Germany expected to see average net income growth of 6.3% next year. Consensus price target broadly unchanged at €84.78. Share price was steady at €51.70 over the past week.
Major Estimate Revision • Aug 21Consensus EPS estimates upgraded to €0.96 lossThe consensus outlook for fiscal year 2024 has been updated. 2024 losses forecast to reduce from -€1.08 to -€0.958 per share. Revenue forecast steady at €60.0m. Biotechs industry in Germany expected to see average net income growth of 6.8% next year. Consensus price target broadly unchanged at €86.33. Share price fell 2.9% to €49.40 over the past week.
Reported Earnings • Aug 18First half 2024 earnings released: €0.58 loss per share (vs €0.11 profit in 1H 2023)First half 2024 results: €0.58 loss per share (down from €0.11 profit in 1H 2023). Revenue: €26.9m (down 39% from 1H 2023). Net loss: €10.1m (down €11.9m from profit in 1H 2023). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Aug 17Now 21% undervaluedOver the last 90 days, the stock has risen 11% to €49.20. The fair value is estimated to be €61.92, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 33% per annum. Earnings are also forecast to grow by 31% per annum over the same time period.
공시 • Aug 06Formycon AG to Report First Half, 2024 Results on Aug 13, 2024Formycon AG announced that they will report first half, 2024 results on Aug 13, 2024
New Risk • Aug 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (24% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding).
분석 기사 • Jul 20A Look At The Fair Value Of Formycon AG (ETR:FYB)Key Insights Using the 2 Stage Free Cash Flow to Equity, Formycon fair value estimate is €60.63 Current share price of...
Valuation Update With 7 Day Price Move • Jun 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €55.80, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 28x in the Biotechs industry in Europe. Total loss to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €55.29 per share.
Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €49.85, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 18% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €26.93 per share.
분석 기사 • May 29Formycon AG's (ETR:FYB) Prospects Need A Boost To Lift SharesFormycon AG's ( ETR:FYB ) price-to-earnings (or "P/E") ratio of 10.3x might make it look like a buy right now compared...
Price Target Changed • May 13Price target decreased by 8.7% to €87.00Down from €95.25, the current price target is an average from 6 analysts. New target price is 104% above last closing price of €42.75. Stock is down 46% over the past year. The company is forecast to post a net loss per share of €1.05 compared to earnings per share of €4.76 last year.
분석 기사 • May 03We Believe Formycon's (ETR:FYB) Earnings Are A Poor Guide For Its ProfitabilityFormycon AG ( ETR:FYB ) recently released a strong earnings report, and the market responded by raising the share...
공시 • May 03Formycon AG to Report Q1, 2024 Results on May 08, 2024Formycon AG announced that they will report Q1, 2024 results on May 08, 2024
Reported Earnings • Apr 25Full year 2023 earnings released: EPS: €4.76 (vs €2.62 in FY 2022)Full year 2023 results: EPS: €4.76 (up from €2.62 in FY 2022). Revenue: €77.7m (up 83% from FY 2022). Net income: €75.8m (up 111% from FY 2022). Profit margin: 98% (up from 85% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
공시 • Apr 13Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024Formycon AG announced that they will report fiscal year 2023 final results on Apr 25, 2024
Price Target Changed • Apr 11Price target decreased by 12% to €96.25Down from €109, the current price target is an average from 4 analysts. New target price is 109% above last closing price of €45.95. Stock is down 31% over the past year. The company is forecast to post earnings per share of €3.38 for next year compared to €2.62 last year.
New Risk • Apr 01New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
Price Target Changed • Jan 31Price target decreased by 7.9% to €103Down from €112, the current price target is an average from 5 analysts. New target price is 101% above last closing price of €51.30. Stock is down 38% over the past year. The company is forecast to post earnings per share of €0.023 for next year compared to €2.62 last year.
공시 • Jan 30Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million. Security Name: Bearer Shares Security Type: Common Stock Securities Offered: 1,603,877 Price\Range: €51.65 Transaction Features: Subsequent Direct Listing
분석 기사 • Jan 19Some Confidence Is Lacking In Formycon AG's (ETR:FYB) P/SWith a price-to-sales (or "P/S") ratio of 11.4x Formycon AG ( ETR:FYB ) may be sending bearish signals at the moment...
분석 기사 • Dec 23We Think Formycon (ETR:FYB) Needs To Drive Business Growth CarefullyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • Oct 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (45% increase in shares outstanding).
분석 기사 • Sep 26Formycon AG's (ETR:FYB) Share Price Not Quite Adding UpYou may think that with a price-to-sales (or "P/S") ratio of 12.8x Formycon AG ( ETR:FYB ) is a stock to avoid...
Reported Earnings • Sep 08First half 2023 earnings released: EPS: €0.11 (vs €6.51 in 1H 2022)First half 2023 results: EPS: €0.11 (down from €6.51 in 1H 2022). Revenue: €43.8m (up 148% from 1H 2022). Net income: €1.80m (down 98% from 1H 2022). Profit margin: 4.1% (down from 454% in 1H 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth.
공시 • Aug 24Formycon AG to Report First Half, 2023 Results on Aug 30, 2023Formycon AG announced that they will report first half, 2023 results on Aug 30, 2023
Major Estimate Revision • Aug 09Consensus EPS estimates fall by 146%The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €81.3m to €78.3m. Losses expected to increase from €0.51 per share to €1.26. Biotechs industry in Germany expected to see average net income growth of 6.1% next year. Consensus price target of €116 unchanged from last update. Share price was steady at €67.10 over the past week.
Price Target Changed • Jul 24Price target decreased by 8.6% to €116Down from €126, the current price target is an average from 2 analysts. New target price is 82% above last closing price of €63.50. Stock is down 18% over the past year. The company is forecast to post a net loss per share of €0.49 compared to earnings per share of €2.62 last year.
공시 • Jun 29Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)Formycon AG nd its license partner Klinge Biopharma GmbH (“Klinge“) announce that the biologics license application (BLA) for FYB203, a biosimilar candidate for Eylea®1 (Active ingredient: Aflibercept) has been submitted to the U.S. Food and Drug Administration („FDA“) in line with the initial schedule. Within 60 days after submission, FDA is expected to decide on whether to accept and to further review the BLA (“file acceptance”). Eylea® is used in the treatment of neovascular age-related macular degeneration (“nAMD”) and other severe retinal diseases. It inhibits vascular endothelial growth factor (“VEGF”), which is responsible for the excessive formation of blood vessels in the retina. With global sales of around USD 9.6 billion[i] Eylea® is currently the top-selling drug in this therapeutic area.
Valuation Update With 7 Day Price Move • May 18Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €77.60, the stock trades at a trailing P/E ratio of 34.6x. Average forward P/E is 32x in the Biotechs industry in Europe. Total returns to shareholders of 209% over the past three years.
Reported Earnings • Apr 30Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2022 results: EPS: €2.62 (up from €1.22 loss in FY 2021). Revenue: €42.5m (up 15% from FY 2021). Net income: €36.0m (up €49.5m from FY 2021). Profit margin: 85% (up from net loss in FY 2021). The move to profitability was primarily driven by lower expenses. Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates by 114%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 93% per year but the company’s share price has only increased by 46% per year, which means it is significantly lagging earnings growth.
공시 • Feb 03Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million. Security Name: Shares Security Type: Common Stock Securities Offered: 910,000 Price\Range: €77 Transaction Features: Rule 144A; Subsequent Direct Listing
Price Target Changed • Nov 16Price target increased to €126Up from €97.67, the current price target is an average from 3 analysts. New target price is 70% above last closing price of €74.30. Stock is up 50% over the past year. The company is forecast to post earnings per share of €3.19 next year compared to a net loss per share of €1.22 last year.
분석 기사 • Nov 05We Think You Should Be Aware Of Some Concerning Factors In Formycon's (ETR:FYB) EarningsThe recent earnings posted by Formycon AG ( ETR:FYB ) were solid, but the stock didn't move as much as we expected. We...
Reported Earnings • Oct 31First half 2022 earnings released: EPS: €6.51 (vs €0.92 loss in 1H 2021)First half 2022 results: EPS: €6.51 (up from €0.92 loss in 1H 2021). Revenue: €17.6m (down 13% from 1H 2021). Net income: €80.0m (up €90.2m from 1H 2021). Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Germany. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 32% per year, which means it is significantly lagging earnings growth.
공시 • Sep 20Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)Formycon AG announced details of a previously undisclosed project in its development pipeline. FYB206 is a biosimilar candidate for Keytruda® (pembrolizumab) and the development is at an advanced preclinical stage. In addition to biosimilars in the field of ophthalmology (FYB201/FYB203), immunology (FYB202) and two further yet unpublished biosimilar candidates (FYB208/FYB209), Formycon is expanding its therapeutic range with FYB206 to the rapidly growing field of immuno-oncology. The active ingredient pembrolizumab is a humanized monoclonal antibody that belongs to the group of immune checkpoint inhibitors and is established in the treatment of a variety of tumors. Pembrolizumab binds to the PD-1 receptor and specifically blocks the interaction between PD-1 and its ligand PD-L1. This helps the immune system activate the body's own cellular anti-tumor immune response and kill e.g. melanoma cells. Since 2015, Keytruda® has been established for the treatment of advanced melanoma, lung and other types of carcinoma. In 2021, the reference market for Keytruda® was reported at a size of more than USD 17 billion worldwide.[i] Expert analyses predict that Keytruda® will become the world's top-selling drug in 2023, with annual revenue potential expected to be well over USD 20 billion as early as 2025. The development and commercialization rights for FYB206 are fully owned by Formycon. Important IP has already been created and patent applications have been filed, with data from the development of alternative formulations. Following convincing results from the extensive analytical protein characterization as well as significant progress in the development of the manufacturing process, a comprehensive data package is currently being compiled in order to closely align further program steps in Scientific Advice Meetings with the EMA and FDA in the second half of the year. Adjusting the manufacturing process to commercial scale is planned for the end of 2022. For this purpose, Formycon has already secured GMP manufacturing capacities at a renowned contract manufacturer.
Price Target Changed • Sep 19Price target increased to €107Up from €95.67, the current price target is an average from 3 analysts. New target price is 53% above last closing price of €70.30. Stock is up 36% over the past year. The company is forecast to post earnings per share of €3.05 next year compared to a net loss per share of €1.22 last year.
Major Estimate Revision • Sep 07Consensus forecasts updatedThe consensus outlook for 2022 has been updated. Forecast profits in 2022 with EPS up from -€1.09 to €3.05 per share. Revenue forecast unchanged from last update at €41.9m. Biotechs industry in Germany expected to see average net income growth of 8.6% next year. Consensus price target of €97.67 unchanged from last update. Share price fell 4.4% to €72.20 over the past week.
분석 기사 • Sep 04We're Hopeful That Formycon (ETR:FYB) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
공시 • Aug 29Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)Formycon AG (“Formycon”), Polpharma Biologics Group BV (“Polpharma Biologics”) and Bioeq AG (“Bioeq”) jointly announce that the European Commission (“EC”) has granted marketing authorization (“MA”) for Ranivisio (Ranivisio - Ranibizumab), a biosimilar to Lucentis (ranibizumab-injection), for the treatment for several serious retinal diseases in the European Union. EC approval follows a positive opinion issued in June 2022 by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and is applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein. Ranivisio is indicated for the treatment of neovascular (wet) age-related macular degeneration (nAMD), the treatment of visual impairment due to diabetic macular oedema (DME) or choroidal neovascularization (CNV), the treatment of proliferative diabetic retinopathy (PDR), as well as the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). FYB201/Ranivisio was developed by Bioeq, a Joint Venture between Formycon and Polpharma Biologics. Mid 2021, Teva Pharmaceutical Industries Ltd. (“Teva”) entered into a strategic partnership for the exclusive commercialization of FYB201 in Europe and selected other countries. Commercial launches across Europe are planned over the coming year, and the treatment is already available in the UK under the tradename Ongavia3, following its approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022. The EU-approval is based on the totality of evidence including analytical, nonclinical, clinical and manufacturing data. In a randomized, double-masked, parallel group, multicenter phase III study (COLUMBUS-AMD) it was shown that Ranivisio is highly similar to the reference product Lucentis in terms of comparable efficacy, safety, pharmacokinetics and immunogenicity in patients with age-related neovascular (wet) macular degeneration. AMD is caused by excessive growth of blood vessels in the retina. Ranibizumab inhibits vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of these blood vessels in the retina. In developed countries AMD is the most common cause of severe visual impairment or blindness and it is estimated that up to 77 million Europeans will be affected by 2050. The consequences of AMD carry a significant burden for healthcare systems and societies as the increasing incidence of the condition is expected to absorb considerable amounts of healthcare resources and funds across the EU.
공시 • Aug 27Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to LucentisFormycon AG announced that the European Commission (EC) has granted marketing authorization (MA) for Ranivisio®, a biosimilar to Lucentis® (ranibizumab-injection) for medical use in the European Union (EU). FYB201/Ranivisio® was developed by Bioeq, a Joint Venture between Formycon and Polpharma Biologics. Mid 2021, Teva Pharmaceutical Industries Ltd. (Teva) entered into a strategic partnership for the exclusive commercialization of FYB201 under the brand name Ranivisio® in the EU. The commercial launch of Ranivisio® in the EU is planned as soon as possible. The European Commission now followed the positive opinion issued by the Committee for Medicinal Products for Human Use ("CHMP") in June 2022 and approved Ranivisio® for the treatment of neovascular (wet) age-related macular degeneration (nAMD), the treatment of visual impairment due to diabetic macular oedema (DME) or choroidal neovascularization (CNV), the treatment of proliferative diabetic retinopathy (PDR) as well as the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO). The EU-approval is based on a totality of evidence including analytical, nonclinical, clinical and manufacturing data. In a randomized, double-masked, parallel group, multicenter phase III study (COLUMBUS-AMD) it was shown that Ranivisio® is highly similar to the reference product Lucentis® in terms of comparable efficacy, safety, pharmacokinetics and immunogenicity in patients with age-related neovascular (wet) macular degeneration.
공시 • Aug 16Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III StudyFormycon AG reported positive preliminary efficacy and safety data from VESPUCCI Phase III clinical trial for FYB202, its proposed biosimilar version of Stelara-(Ustekinumab). The multi-center, randomized, double-blinded, comparative clinical study met the primary efficacy endpoint, demonstrating comparable efficacy between FYB202 and the reference medicine Stelara- in patients with moderate to severe psoriasis vulgaris (plaque psoriasis). This is the most common form of psoriasis, accounting for 80% to 90% of all cases. The primary endpoint of the comparative global Phase III study measures the % improvement of the Psoriasis Area and Severity Index (PASI) at 12 weeks from baseline. The values obtained for FYB202 and reference product are within the relevant equivalence limits. In addition, to date, no clinically meaningful differences in safety and immunogenicity have been observed. The extended Phase I pharmacokinetics study has commenced. Recruitment is evolving according to plan and a substantial number of subjects has already been enrolled in the study. The active ingredient ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23. Since 2009, Stelara- has been used to treat various severe inflammatory conditions such as moderate to severe psoriasis as well as psoriatic arthritis. Its approved indications were expanded to chronic inflammatory bowel diseases like treatment of Crohn's disease (2016) and ulcerative colitis (2019). Stelara- achieved a global sales volume of over USD 9 billion in 2021. As a result of the transaction with ATHOS KG, which was successfully concluded in the first half of 2022, the global commercialization rights to FYB202 are held in full by Formycon AG (prior to the transaction 24.9% co-ownership share).
공시 • Aug 04Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2Formycon AG announced that the U.S. Food and Drug Administration ("FDA") has approved CIMERLIT (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis- (ranibizumab injection). FYB201 was developed by Bioeq AG, a Joint Venture between Formycon AG and Polpharma Biologics Group BV. End of the year 2019, Coherus BioSciences Inc. ("Coherus") entered into a license agreement for the exclusive commercialization of FYB201 under the brand name CIMERLIT in the United States of America ("U.S."). The commercial launch of CIMERLIT, in both 0.3mg and 0.5mg dosages, in the U.S. by Coherus, is planned for early October 2022. CIMERLIT obtained approval from FDA for the treatment of Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal diseases such as Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema following Retinal Vein Occlusion (RVO) and Myopic Choroidal Neovascularization (mCNV). CIMERLIT is the first and only interchangeable biosimilar with an exclusivity for 12 month after market launch, that is indicated for the treatment of all five Lucentis- indications and as such is a new medical option for patients with serious retinal diseases. FDA-approval and interchangeability designation are based on a totality of evidence including analytical, nonclinical, clinical and manufacturing data. Efficacy, safety, pharmacokinetics and immunogenicity of CIMERLIT were found to be comparable to the reference drug Lucentis- in patients with Age-Related Neovascular (wet) Macular Degeneration (nAMD).
분석 기사 • Jul 13Analysts Just Published A Bright New Outlook For Formycon AG's (ETR:FYB)Shareholders in Formycon AG ( ETR:FYB ) may be thrilled to learn that the analysts have just delivered a major upgrade...
Major Estimate Revision • Jul 12Consensus revenue estimates increase by 13%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from €32.9m to €37.1m. Forecast losses expected to reduce from -€1.44 to -€1.09 per share. Biotechs industry in Germany expected to see average net income growth of 11% next year. Consensus price target up from €93.00 to €95.67. Share price fell 3.0% to €74.00 over the past week.
공시 • Jul 02Formycon AG Announces Supervisory Board and Executive ChangesFormycon AG at it's AGM elected Dr. Thomas Strüngmann to the Supervisory Board and Dr. Andreas Seidl, the future Chief Scientific Officer (CSO), who was appointed to the Management Board by the Supervisory Board effective July 01, 2022.
공시 • Jun 25Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMAFormycon AG and its licensing partner Bioeq AG announced that the Committee for Medicinal Products for Human Use ("CHMP") of the European Medicines Agency ("EMA") issued a positive opinion for FYB201, a biosimilar to Lucentis. FYB201 has thus been recommended for approval in the European Union (EU) for the treatment of patients with age-related neovascular (wet) macular degeneration (AMD) and other serious ocular diseases such as diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), macular edema due to retinal vein occlusion (branch RVO or central RVO) and choroidal neovascularization (CNV). The CHMP recommendation is based on an in-depth evaluation of a comprehensive set of data for comparative analytical characterization and commercial-scale manufacturing. In a randomized, double-blind, multicenter, parallel-group Phase III study, FYB201 also demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference drug Lucentis- (ranibizumab) in patients with age-related neovascular (wet) macular degeneration.Within the approval process, the CHMP's favorable opinion represents an important regulatory step towards the approval of FYB201 in the European Union. The CHMP's scientific assessment report forms the basis for the European Commission's decision to grant a central marketing authorization, which is expected at the end of August.
분석 기사 • Jun 02Bearish: Analysts Just Cut Their Formycon AG (ETR:FYB) Revenue and EPS estimatesThe latest analyst coverage could presage a bad day for Formycon AG ( ETR:FYB ), with the analysts making...
Major Estimate Revision • Jun 01Consensus revenue estimates fall by 17%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €39.4m to €32.9m. Forecast losses increased from -€0.97 to -€1.44 per share. Biotechs industry in Germany expected to see average net income growth of 10% next year. Consensus price target up from €91.00 to €93.00. Share price rose 4.1% to €74.50 over the past week.
분석 기사 • May 23Here's Why We're Not Too Worried About Formycon's (ETR:FYB) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • May 22Full year 2021 earnings: EPS and revenues miss analyst expectationsFull year 2021 results: €1.22 loss per share (down from €0.54 loss in FY 2020). Revenue: €37.0m (up 8.0% from FY 2020). Net loss: €13.5m (loss widened 127% from FY 2020). Products in clinical trials Phase III: 2 Revenue missed analyst estimates by 9.5%. Earnings per share (EPS) also missed analyst estimates by 2.6%. Over the next year, revenue is forecast to grow 6.6%, compared to a 29% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 132 percentage points per year, which is a significant difference in performance.
